# Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

> **NCT06389760** · PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 57 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** mFOLFIRINOX
- **DRUG:** GX

## Key facts

- **NCT ID:** NCT06389760
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06389760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06389760, "Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06389760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*